First indigenous vaccine for Pneumonia launched by Serum Institute of India (SII)

The Serum Institute of India (SII) has announced the launch of India’s first indigenously developed vaccine PNEUMOSIL that has been developed in collaboration among Serum Institute of India Pvt Ltd , PATH and Bill and Melinda Gates foundation.

“The composition of the WHO pre-qualified vaccine is specially tailored as per the prevalence of the Top 10 serotypes of S. pneumoniae in India and other regions of the world, which is the unique feature of this conjugate vaccine.” Say’s statement given by Serum Institute of India

The vaccine will provide effective and long-lasting protection for children against pneumococcal diseases.

 “It is a great moment of pride to witness Serum Institute take forward the ‘Make in India’ legacy, with the launch of India’s first indigenously developed Pneumococcal Conjugate Vaccine. It is a significant milestone for the country’s public health care which will ensure that children are protected better against Pneumococcal disease with an affordable and high-quality vaccine.  I am sure, Serum Institute of India will continue their endeavour to develop many more life saving vaccines in future also on the lines of clarion call of our Hon’ble Prime Minister “VOCAL FOR LOCAL” and fulfill our Hon’ble Prime Minister’s dream “ATMANIRBHAR BHARAT””, say’s  Dr. Harsh Vardhan, Union Minister, Ministry of Health & Family Welfare 

 “Over the years our constant endeavor has been to provide high quality vaccines with regular supplies which ensures excellent immunization coverage to children and families worldwide. With that thought we have developed this PCV with a unique composition based on the serotype prevalence in India. This makes our PCV an ideal choice for protecting our children from pneumococcal disease. While the vaccine itself is of the highest quality and grade available, vaccine accessibility is of utmost importance as well, and to ensure ease of access by making it available at an affordable price. With the best PCV, we hope to bring down the mortality rate significantly while also making our country self-sufficient with a robust public health care system.” shared Adar Poonawalla, CEO of Serum Institute of India.